Request for Sample
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Global Cancer Vaccines Market Overview
“The global Cancer Vaccines market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031.”
The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026.
The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cancer vaccines market report has been segmented on the basis of treatment method, type, application, and region.
Vaccines can be used in the treatment of cancer as they can recognize proteins that are present in particular cancer cells. Cancer vaccines provide numerous benefits as they can stop the growth of cancerous cells, prevents cancer relapse, and destroy cancer cells that are left behind after other treatment.
Many different types of vaccines are used for the treatment of cancer such as antigen vaccines which boost the immune systems instead of using whole tumor cells and can be targeted to specific cancer types. Vector-based vaccines can be used to deliver more than one cancer antigen at a time.
Increasing incidence of cancer such as breast cancer, prostate cancer, and lung cancer globally is expected to fuel the growth of the global cancer vaccines market over the forecast period. Continuous development by manufacturers for the development of new vaccines is expected to boost the growth of the global cancer vaccines market over the forecast period.
High cost and time incurred in the development of cancer vaccines are factors restraining the growth of the market over the forecast period.
However, technological advancements and innovations focusing on the development of specific and effective cancer treatments are expected to create new opportunities for major players in the global cancer vaccines market over the forecast period.
North America market dominates the global cancer vaccines market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the presence of dominant players in the market and the well-developed healthcare infrastructure in the region.
Europe accounts for the second-largest revenue share contribution to the global cancer vaccines market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years owing to the increasing incidence of cancer in the region.
Global cancer vaccines market segmentation;
By treatment method:
- Preventive cancer vaccines
- Therapeutic cancer vaccines
- Subunit Vaccines
- Live Attenuated Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Recombinant Vector Vaccines
- Viral Vector and DNA Vaccines
- Cervical cancer
- Prostate cancer
- Lung cancer
- Breast cancer
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Astrazeneca plc.
- Glaxosmithkline Plc.
- Merck & Co., Inc.
- Aduro BioTech Inc.
- Prima BioMed
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- Sanofi SA
- Gritstone Oncology, Inc.
- PaxVax Corporation
Request for TOC
Don't just take our word. We are trusted by these great companies!